<DOC>
	<DOCNO>NCT00348296</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled multi-center study carry assess efficacy GB-0998 treatment systemic sclerosis base change modify Rodnan total skin thickness score ( TSS ) primary endopoint , addition , assess safety GB-0998 .</brief_summary>
	<brief_title>Efficacy Safety Study GB-0998 Treatment Systemic Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients sclerosis locate proximal elbow joint diffuse systemic scleroderma . Patients less 20 point TSS . Patients appropriate therapeutic treatment . Patients severe hepatic disorder , severe renal disorder severe heart disorder . Patients malignant tumor . Patients anamnesis shock hypersensitivity drug . Patients anamnesis cerebral infarction symptom disease . Patients diagnose IgA deficiency past history . Pregnant , lactating , probably pregnant patient , patient want become pregnant . Patients dose increase new dose steroid within 12 week consent . Patients administer investigational drug within 12 week consent .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Scleroderma , Systemic</keyword>
</DOC>